Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONDUCT study of nivolumab versus nivolumab + docetaxel in previously treated advanced non-small-cell lung cancer
jRCTs031180331Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Nivolumab with Nivolumab + docetaxel (2 arms). Primary endpoints: 6-month progression-free survival rate, Grade 3 or higher pneumonitis rate and 1 more. Started Dec 2017; status: completed.
02
Drugs
nivolumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180331.